Topics:
Thoracic Malignancies • Medical Oncology
How would you treat a patient with emergence of EGFR C797S mutation at the time of progression on osimertinib given for EGFR T790M mutation?
Would your choice of treatment change if the same patient was T790M negative and osimertinib was given as a first-line therapy?
Answer from: Medical Oncologist at Community Practice
Although I don't have a personal experience, there are reports of adding 1st or 2nd gen EGFR TKI such as gefitinib or erlotinib to Osimertinib.J Thorac Oncol. 2017 Nov;12(11):1728-1732. doi: 10.1016/j.jtho.2017.08.006. Epub 2017 Aug 24.Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mu...
Sign in or Register to read more